



Oregon Prescription Drug
Affordability Board



Constituent Focus Group Discussions Session 2

Focus Group
May – July 2024


Meeting Agenda

- Introductions and Welcome from Myers and Stauffer
- UPL Presentation (Refresher)
 - Drug and Pricing Flow
 - Basics of UPL Acquisition Cost, Billing and Payment
- Continuation of Constituent Group Discussion and Feedback




Supply Chain Impacts: Drug and Pricing Flow


Retail



Health-System/Physician-Administered



Basics of UPL acquisition cost, billing, and payment



Note: UPL replaces WAC, AWP, AAC, EAC etc. UPL is the metric for all financial transactions for ingredient cost. Like existing metrics, there will be 'UPL minus' in the supply chain.

Dispensing or administration fees, independent of ingredient cost, may still be charged by pharmacies or the health care provider administering the drug to the patient.



Group Discussion

- Impact of Drug Affordability
 - UPL Impact
 - UPL Implementation
 - UPL Methodologies
 - Desired State of Drug Affordability
 - Recommendations
 - Final Thoughts
- Written feedback related to the UPL focus group discussions or the survey concepts may be provided to OregonPDAB@mslc.com . Please provide this feedback by 6/4/2024.
 - You may also participate in the public comment process by writing and submitting a letter to the board or signing up to speak during a board meeting. The participation form may be found here <https://dfr.oregon.gov/pdab/Pages/public-comment.aspx>

